ice36casino| Hengrui Pharmaceutical (600276.SH): Subsidiary SHR-A1921 for injection is expected to be included in the public list of breakthrough treatment varieties

Zhitong Finance APP News, Hengrui Pharmaceutical (600276ice36casino.SH) issued an announcement that the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd.ice36casinoSHR-A1921 for injection is planned to be included in the publicity list of breakthrough treatment varieties by the Center for Drug Evaluation of the State Food and Drug Administration, with a publicity period of 7 days. Proposed indications (or functions) for this drugice36casino: Used for the treatment of platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer.

27 05

2024-05-27 04:18:47

Back to
Category Back to
Homepage

topnftearninggames| Shenzhen Ruijie: Demand for services such as testing and identification is accelerating and the company has actively followed up on relevant policies bestvideopokerpayouts| Evergrande Automobile: 29% of shares were acquired immediately, 29.5% of shares became the subject of options, and trading resumed on May 27

ice36casino| Hengrui Pharmaceutical (600276.SH): Subsidiary SHR-A1921 for injection is expected to be included in the public list of breakthrough treatment varieties

Related content